8-K: Aclarion Releases Updated Investor Presentation Amid Planet MicroCap Showcase Appearance

Aclarion, Inc. announces the release of an updated investor presentation in conjunction with its appearance at the Planet MicroCap Showcase: VEGAS 2025, highlighting strategic and financial updates.

Summary

• Aclarion, Inc. released an updated investor presentation on April 23, 2025, coinciding with its presentation at the Planet MicroCap Showcase: VEGAS 2025.
• The presentation highlights Aclarion's focus on addressing chronic low back pain using its Nociscan platform, which leverages biomarkers and AI algorithms.
• Aclarion reported nearly $14.6 million in cash on hand as of its 10K filing on April 9, 2025, providing a cash runway into Q3 2026.
• The company has secured meaningful payer approvals in England and is expanding physician referral and commercial support for Nociscan in the U.S.
• The pivotal CLARITY trial is fully funded through initial interim results, expected in Q2 2026, with total CLARITY costs estimated at $4.6 million.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with a strong cash position, payer coverage in the UK, and a fully funded pivotal trial. However, it also acknowledges risks and uncertainties inherent in the industry.

Positives

• Aclarion has a strong cash position of nearly $14.6 million.
• The company has a clean capital structure with no debt or preferred shares.
• Aclarion has secured payer approvals in the UK for Nociscan.
• The CLARITY trial is fully funded, with interim results expected in Q2 2026.
• Aclarion has secured CPT Category III codes for reimbursement of Nociscan.

Risks

• The forward-looking statements are subject to risks and uncertainties detailed in the company's SEC filings, including the Annual Report on Form 10-K for the year ended December 31, 2024.
• The industry in which Aclarion operates is subject to a high degree of uncertainty and risk due to a variety of factors.

Future Outlook

The company anticipates improved clinical results when using Nociscan, as demonstrated in the CLARITY trial.

Management Comments

• Brent Ness, Chief Executive Officer of Aclarion, will be presenting on the Company and recent value-driving initiatives.

Industry Context

Aclarion is addressing the chronic low back pain market, which represents a significant healthcare expenditure in the U.S., estimated at up to $134.5 billion.

Comparison to Industry Standards

• The presentation references Medtronic, HeartFlow and Cleerly as comparables.
• The presentation references the London Clinic as a customer.
• The presentation references the European Spine Journal as a publication for clinical studies.

Stakeholder Impact

• Shareholders: The presentation provides updates on the company's financial position and strategic initiatives.
• Physicians: Nociscan aims to provide better data for improved patient care.
• Patients: Nociscan offers a non-invasive diagnostic tool for chronic low back pain.

Next Steps

• Continue the CLARITY pivotal trial and expect initial interim results in Q2 2026.
• Expand physician referral and commercial support for Nociscan in the U.S.
• Increase volume of Category III code billing and partner with surgeon KOLs & societies to engage payers.
• Leverage KOLs to increase market awareness and usage of Nociscan.

Key Dates

Keywords

Nociscan, Aclarion, Investor Presentation, Low Back Pain, Biomarkers, CLARITY Trial, Payer Coverage, Nasdaq, Healthcare Technology, AI Algorithms